ETX101 reduced seizures and improved neurodevelopmental outcomes, but its impact was unexpectedly attenuated by using the ...
Encoded Therapeutics gives a heads-up to other gene therapy company about the trade-offs with a drug meant to improve safety.
New POLARIS Phase I/II data presented at ASGCT show ETX101 gene therapy reducing seizures and improving neurodevelopment in ...
Encoded Therapeutics Presents New Clinical Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the ASGCT 2026 Presidential Symposium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results